Compound class:
Synthetic organic
Comment: Bromo-deaza-SAH is a small molecule inhibitor of the chromatin modifying enzymes DOT1-like histone H3K79 methyltransferase (DOT1L) and DNA (cytosine-5-)-methyltransferase 1 (DNMT1).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects |
S-adenosylhomocysteine (SAH) is a product of SAM (S-adenosyl methionine)-dependent methyltransferase activity, which feeds-back to inhibit these methyltransferases. Bromo-deaza-SAH is an analogue of SAH which mimics the effect of SAH on the enzymatic activity of the lysine methyltransferase, DOT1L (aka KMT4) and which is 8-fold more potent than SAH [4]. By inhibiting DOT1L activity, bromo-deaza-SAH should reduce the aberrant methylation of lysine 79 of histone H3 (H3K79), which is associated with some lymphoid leukemias [1-3]. |